Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890712 | 0.81 | P2RX7 (0.47) | P2RX7MAPK1 | |
| SCHEMBL17397061 | 0.78 | P2RX7 (0.49) | P2RX7MAPK1 | |
| SCHEMBL18984390 | 0.76 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL1441509 | 0.76 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL30965858 | 0.74 | P2RX7 (0.80) | P2RX7MAPK1 | |
| SCHEMBL25916643 | 0.73 | LPL (0.47) | P2RX7CHRM1CHRM2CHRM3CHRNB2 | |
| SCHEMBL23705580 | 0.72 | P2RX7 (0.43) | P2RX7MAPK1CHRM1CHRM2CHRM5 | |
| SCHEMBL22290586 | 0.72 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL31342196 | 0.72 | P2RX7 (0.43) | P2RX7MAPK1CHRNB2CHRNA4 | |
| SCHEMBL12696582 | 0.71 | P2RX7 (0.42) | P2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4673136-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Vanderbilt University (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-12377084-B2 | ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4447954-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | Icahn School of Medicine at Mount Sinai (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024182692-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024145623-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377084-B2 | ERAP1 modulators | ERAP1, NR1I3, HRH4 | P2RX7 882/4885MAPK1 2214/4885CHRM1 841/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | P2RX7 1829/4885MAPK1 343/4885CHRM1 4875/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | P2RX7 1724/4885MAPK1 582/4885CHRM1 3578/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | P2RX7 4746/4885MAPK1 136/4885CHRM1 804/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | P2RX7 1408/4885MAPK1 634/4885CHRM1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.